| Drug Name: | Theophylline (58-55-9) |
|---|---|
| PubChem ID: | 2153 |
| SMILES: | CN1C2=C(C(=O)N(C1=O)C)NC=N2 |
| InchiKey: | ZFXYFBGIUFBOJW-UHFFFAOYSA-N |
| Therapeutic Category: | Anti-Asthmatic Agents, Autonomic Agents, Bronchodilator Agents, Cardiovascular Agents, Enzyme Inhibitors, Neurotransmitter Agents, Peripheral Nervous System Agents, Phosphodiesterase Inhibitors, Purinergic Agents, Purinergic Antagonists, Purinergic P1 Receptor Antagonists, Respiratory System Agents, Vasodilator Agents |
| Molecular Weight (dalton) | : | 180.167 |
| LogP | : | -1.0397 |
| Ring Count | : | 2 |
| Hydrogen Bond Acceptor Count | : | 5 |
| Hydrogen Bond Donor Count | : | 1 |
| Total Polar Surface Area | : | 72.68 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Lomustine (13010-47-4) | Thrombocytopenia | Synergistic | theophylline inhibited the activity of phosphodiesterase within the platelets, thereby increasing cyclic AMP levels and disrupting normal platelet function, while lomustine causes thrombocytopenia. | Theophylline-induced lomustine toxicity |
| Dipyridamole (58-32-2) | Reduce The Effects Of Dipyridamole | Antagonistic | theophylline might antagonise effects of dipyridamole becauseact as competitive antagonists of adenosine | Effect of maintenance oral theophylline on dipyridamole-thallium-201 myocardial imaging using SPECT and dipyridamole-induced hemodynamic changes |
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Bradycardia | Renin (P00797) | Theophylline increased renin release significantly at a renal perfusion pressure,which leads to the greater effect at low blood pressure. [ ADR Type 1 ] | Conditions for augmentation of renin release by theophylline Scand |
| Dangerous Side Effects | Cytochrome P450 2E1 (P05181) | Erythromycin inhibits CYP2E1 activity@thus increases the level of theophylline in blood and causes dangerous side effects [ ADR Type 4 ] | Acute drug prescribing to children on chronic antiepilepsy therapy and the potential for adverse drug interactions in primary care |
| Emesis | Acid sphinGOmyelinase-like phosphodiesterase (Q92484) | Emetic side effect of xanthine bronchodilators results from the inhibition of one or more forms of phosphodiesterase (PDE). [ ADR Type 1 ] | Mechanism for the emetic side effect of xanthine bronchodilators |
| Metabolic Acidosis | Alanine aminotransferase (P24298) | Metabolic acidosis [ ADR Type 2 ] | Massive theophylline overdose with atypical metabolic abnormalities |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|---|---|
| Caffeine | Increases The Risk Of Drug Toxicity | Food-Drug Interactions |
| High-fat meal and grape fruit juice | Increase Bioavailability | Food-Drug Interactions |
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category